Chaotropy retweeted
The European Commission has granted marketing authorization for our oral RAS(ON) multi-selective inhibitor for previously treated metastatic pancreatic cancer.
Read more: revmed.com/media/news/13736/…
#ForMediaOnly
Chaotropy retweeted
Palisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative Colitis
bit.ly/4dXWZfC
$PALI #UlcerativeColitis #Crohnsdisease #IBD #GIHealth
Chaotropy retweeted
Today we’re presenting late-breaking results from our Phase 2 AMPLIFY-7P study evaluating camupepimut (ELI-002 7P) in patients with resected pancreatic cancer at #ESMO26, as well as in a Nature Medicine publication. Read more about the study results here: bit.ly/4snQBEr
Chaotropy retweeted
A new vaccine continues to show potential as a ready-made treatment for pancreatic cancer, according to a study co-led by MSK researchers.
MSK's @EileenMOReilly presented phase 2 results from AMPLIFY-7P at #ESMO26. The vaccine targets KRAS mutations, which are found in more than 90% of pancreatic cancers.
99% of patients receiving the vaccine developed cancer-fighting immune T cells. Patients with the strongest immune responses had the lowest recurrence rates.
“Having a vaccine that’s ‘off-the-shelf’ would make it easier, faster, and less expensive to treat a larger number of patients,” says Dr. O’Reilly. “This gives hope for people with pancreatic cancer who have been out of effective treatments when their disease returns.” Learn more: bit.ly/3VSsO3h
Nature research paper: Hepatocytes promote liver metastasis of pancreatic cancer by providing serine
go.nature.com/4hwk1v4
Chaotropy retweeted
Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBD
bit.ly/4xEMEMm
$PALI #UlcerativeColitis #Crohnsdisease #IBD #GIHealth
Chaotropy retweeted
No day shall ever erase you from the memory of time.
Nulla dies umquam memori vos eximet aevo.
Virgil, Aeneid 9.447
Chaotropy retweeted
Today, we announced our second quarter 2026 financial results and shared our latest business updates. Read our press release to learn more about our commercial progress and updates on our RAS/MAPK pathway driven pipeline programs.
investor.verastem.com/news-r…
#VerastemOnc
Chaotropy retweeted
We are looking forward to hosting an investor conference call and webcast to share progress and updated preliminary data from the Phase 1/2 TARGET-D 101 VS-7375 oral KRAS G12D (ON/OFF) dose escalation and dose expansion trial evaluating VS-7375 alone and in combination in patients with KRAS G12D-mutated advanced solid tumors.
A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, investor.verastem.com/events.
investor.verastem.com/news-r…
$VSTM
Chaotropy retweeted
Preclinical data published in a peer-reviewed manuscript in Science Advances, published by @aaas, demonstrated robust T cell activation, durable immune memory, and a lymph node-targeted mechanism that supports next-generation immunotherapies. bit.ly/4u6ABpi $ELTX
Chaotropy retweeted
Next week at @PEGSboston, Ahmet Vakkasoglu & Richard DiPaolo will present preclinical data on our TGF-β/IL-2 fusion protein CUE-401, supporting its ability to expand existing T regs and induce new Tregs in #autoimmune & #inflammatory diseases. Join us: pegsummit.com/
Chaotropy retweeted
Additional steady-state pharmacokinetic findings provide mechanistic support for previously reported PALI-2108 Phase 1b clinical activity and support PALI-2108’s potential as a once-daily, gut-targeted oral therapy. More info: bit.ly/4ng0n94
$PALI #DDW2026
Chaotropy retweeted
AI may detect pancreatic cancer before it’s recognizable on CT
~475-day lead time
Higher sensitivity vs radiologists
Early data but promising
Needs prospective validation
@Gut_BMJ *
Chaotropy retweeted
Palisade today announced positive topline data from its Phase 1b clinical study evaluating PALI-2108 in patients with #FibrostenoticCrohnsDisease. Management will host a conference call and webcast tomorrow, March 31st at 8:00 AM ET, for details: bit.ly/4sIlbHW $PALI
$TENX fully enrolled, data Q3.
I’ve gotten a lot of messages asking about my BioPick selection for this year, $TENX. I’ve responded to a few but don’t have the time to respond to everyone.
I actually considered making $TENX an official “pitch”, but I don’t think I can get there on the risk/reward skew to say that this is “one of the best setups I’ve ever seen” like I try to do for “official” pitches.
Still, it’s been an obscure name, and IMO very clearly has a heavily underappreciated 2026 catalyst that many people don't know about, so I think it's worth talking about. I am long currently and there’s a decent chance that I’ll be exposed to the binary - at least I think that I’ll be exposed to the readout if the stock stays at these prices going into the data.
So, I won’t pitch it with a comprehensive thread like $NKTR & $ABVX, and I won’t share my full large diligence document like I did for those. But, I hope the brief (by my standards) discussion here could lead to some solid sharing of thoughts with the “biotwitter” community. Frankly, I'm not even sure the best way to "play" this one, so some feedback and collective diligence here could be useful.
Chaotropy retweeted
Elicio is advancing an innovative pipeline of cancer immunotherapies aimed at addressing critical unmet needs for patients, supported by a seasoned management team. Explore the KRAS opportunity in our corporate presentation: bit.ly/49ODIdl $ELTX




























